Organon & Co. (NYSE:OGN) Given Consensus Rating of “Reduce” by Analysts

Organon & Co. (NYSE:OGN) has received an average rating of “Reduce” from the seven analysts that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and five have assigned a hold recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $11.40.

Several brokerages have recently weighed in on OGN. BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and raised their target price for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Finally, Weiss Ratings upgraded shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 15th.

Insider Activity at Organon & Co.

In other Organon & Co. news, SVP Lynette Holzbaur bought 26,448 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were acquired at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the transaction, the senior vice president owned 52,851 shares in the company, valued at approximately $705,560.85. The trade was a 100.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On Organon & Co.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada boosted its stake in Organon & Co. by 53.4% in the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock valued at $5,374,000 after buying an additional 125,648 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Organon & Co. by 126.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after acquiring an additional 801,307 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Organon & Co. by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock worth $15,530,000 after acquiring an additional 26,640 shares in the last quarter. Focus Partners Wealth lifted its holdings in shares of Organon & Co. by 33.2% during the first quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock valued at $832,000 after acquiring an additional 13,925 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Organon & Co. during the second quarter valued at $107,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $13.51 on Friday. The business has a 50 day moving average price of $13.42 and a 200 day moving average price of $9.73. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.60. The company has a market cap of $3.55 billion, a price-to-earnings ratio of 14.52, a PEG ratio of 1.25 and a beta of 1.54. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.83 by ($0.12). The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.02 earnings per share. Research analysts predict that Organon & Co. will post 3.23 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Monday, May 11th were paid a $0.02 dividend. The ex-dividend date was Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio is currently 8.60%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.